No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Your search for apixaban returned 19 results
Apixaban and rivaroxaban are both factor Xa inhibitors.
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.